Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
395.00    -1.00 (-0.25%)
Bid:
390.00
Ask:
405.00
Spread: 15.00 (3.846%)
Market Cap: £189.59m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Trading update

23 Jul 2012 07:00

RNS Number : 1978I
Tristel PLC
23 July 2012
 



 

 

TRISTEL plc

("Tristel" or "the Company")

 

Trading update

 

Tristel plc, the manufacturer of infection prevention, contamination control and specialist hygiene products, provides a trading update following the end of its financial year on 30 June 2012.

 

As a result of a strong performance in late June in all of Tristel's business segments, both in the UK and overseas, the Company achieved revenues ahead of the level previously indicated in its update on 15 June. Results to 30 June 2012 will now show adjusted pre-tax profits in excess of £700,000. At its year-end the Company had cash balances of £600,000. Tristel intends to announce its preliminary results for the year to 30 June on 29 October 2012.

 

 As reported in the earlier update, the Company changed its business model for the UK veterinary market during the second half of the year. In June, the first of the three major national wholesalers listed the Company's "Anistel" product range. The Company is pleased to report that during July the other two wholesalers have also ordered and been supplied with Anistel products. This is an encouraging milestone for the Company as it seeks to establish Anistel as the dominantbrand in the UK veterinary market. Anistel is the successor brand-name to "Trigene" which has been the market leader for the past decade and which has been manufactured by Tristel since 2009. Alongside these developments, six RSPCA regional branches and the Royal Veterinary College have joined a growing list of veterinary practices that are switching to Anistel. 

 

Paul Swinney, Chief Executive, comments "We are pleased with the progress we are making in establishing direct relationships with the three major national wholesalers who together represent the main distribution route into the UK veterinary market." 

 For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

finnCap

Tel: 020 7600 1658

Geoff Nash (Corporate Finance)

Charlotte Stranner (Corporate Finance)

Simon Starr (Corporate Broking)

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEBLFLLDFXBBZ
Date   Source Headline
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM
12th Dec 20227:00 amRNSAGM Statement
2nd Nov 20221:50 pmRNSHolding(s) in Company
25th Oct 20227:00 amRNSAudited Preliminary Results
6th Oct 20229:15 amRNSIssue of Equity
4th Oct 202212:00 pmRNSAppointment of new Company Secretary
4th Oct 20227:00 amRNSNotice of Results & Investor Presentation
29th Sep 20221:00 pmRNSNorth America update
30th Aug 20227:00 amRNSHolding(s) in Company
22nd Jul 20221:05 pmRNSDirector/PDMR Shareholding
21st Jul 202210:15 amRNSHolding(s) in Company
18th Jul 20224:41 pmRNSSecond Price Monitoring Extn
18th Jul 20224:35 pmRNSPrice Monitoring Extension
18th Jul 20227:00 amRNSTrading update and special dividend
30th Jun 20227:00 amRNSDe Novo FDA submission for Tristel Duo ULT
20th Jun 202210:00 amRNSShareholder Open Day & Notice of Trading update
7th Jun 20221:15 pmRNSHolding(s) in Company
4th May 20227:00 amRNSInvestor Presentation
3rd May 202212:30 pmRNSHolding(s) in Company
14th Apr 202212:00 pmRNSIssue of Equity
6th Apr 202212:10 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.